Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: BOLERO-1 (2015)
- Authors:
- Hurvitz, Sara A.
- Andre, Fabrice
- Jiang, Zefei
- Shao, Zhimin
- Neciosup, Silvia P.
- Mano, Max S.
- Tseng, Ling-Min
- Zhang, Qingyuan
- Shen, Kunwei
- Liu, Donggeng
- Dreosti, Lydia M.
- Feng, Jifeng
- Burris, Howard A.
- Toi, Masakazu
- Buyse, Marc E.
- Cabaribere, David
- Lindsay, Mary-Ann
- Kunz, Tiffany
- Rao, Shantha
- Pacaud, Lida B.
- Taran, Tetiana
- Slamon, Dennis
- Autor USP: MANO, MAX SENNA - FM
- Unidade: FM
- DOI: 10.1158/1538-7445.SABCS14-S6-01
- Subjects: PLACEBO; NEOPLASIAS MAMÁRIAS (FISIOPATOLOGIA); ESTUDOS RANDOMIZADOS
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Cancer Research
- ISSN: 0008-5472
- Volume/Número/Paginação/Ano: v. 75, abst. S6-01, May, 2015
- Conference titles: Annual CTRC-AACR San Antonio Breast Cancer Symposium
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
HURVITZ, Sara A. et al. Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: BOLERO-1. Cancer Research. Baltimore: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1158/1538-7445.SABCS14-S6-01. Acesso em: 24 abr. 2024. , 2015 -
APA
Hurvitz, S. A., Andre, F., Jiang, Z., Shao, Z., Neciosup, S. P., Mano, M. S., et al. (2015). Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: BOLERO-1. Cancer Research. Baltimore: Faculdade de Medicina, Universidade de São Paulo. doi:10.1158/1538-7445.SABCS14-S6-01 -
NLM
Hurvitz SA, Andre F, Jiang Z, Shao Z, Neciosup SP, Mano MS, Tseng L-M, Zhang Q, Shen K, Liu D, Dreosti LM, Feng J, Burris HA, Toi M, Buyse ME, Cabaribere D, Lindsay M-A, Kunz T, Rao S, Pacaud LB, Taran T, Slamon D. Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: BOLERO-1 [Internet]. Cancer Research. 2015 ; 75[citado 2024 abr. 24 ] Available from: https://doi.org/10.1158/1538-7445.SABCS14-S6-01 -
Vancouver
Hurvitz SA, Andre F, Jiang Z, Shao Z, Neciosup SP, Mano MS, Tseng L-M, Zhang Q, Shen K, Liu D, Dreosti LM, Feng J, Burris HA, Toi M, Buyse ME, Cabaribere D, Lindsay M-A, Kunz T, Rao S, Pacaud LB, Taran T, Slamon D. Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: BOLERO-1 [Internet]. Cancer Research. 2015 ; 75[citado 2024 abr. 24 ] Available from: https://doi.org/10.1158/1538-7445.SABCS14-S6-01 - Value of systemic staging in asymptomatic early breast cancer
- Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial
- Reply to [Carta]: mastectomy skin flap thickness
- A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study)
- HER2-targeted therapy in breast cancer: A systematic review of neoadjuvant trials
- Return to work after breast cancer diagnosis: An observational prospective study of 125 patients in South America
- O uso do Oncotype DX® na indicação de quimioterapia adjuvante - experiência do Hospital Sírio-Libanês
- Pneumonite não-infecciosa em paciente com tumor neuroendócrino tratado com everolimus (EVR)
- Multidisciplinary international survey of post-operative radiation therapy practices after nipple-sparing or skin-sparing mastectomy
- Rare tumors research in emerging countries
Informações sobre o DOI: 10.1158/1538-7445.SABCS14-S6-01 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas